Differences in outcomes with anti-EGFR treatment in mCRC may be attributed to tumor genomic and molecular profiles associated with primary resistance to EGFR inhibition, such as the BRAF V600E mutation and high microsatellite instability (MSI-H), among others5–7. This evidence concerns the gene BRAF and neoplasm.